Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors

Prof Srinivas Tantravahi - University of Utah, Salt Lake City, USA
Efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors ( Prof Srinivas Tantravahi - University of Utah, Salt Lake City, USA )
20 Dec 2021

Significance of gut microbiota in patients receiving CAR T cell immunotherapy

Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA
Significance of gut microbiota in patients receiving CAR T cell immunotherapy ( Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA )
17 Dec 2021

Cancer medicine shortages for children around the world

Dr Carlos Rodriguez-Galindo - St. Jude Children’s Research Hospital, Memphis, USA
Cancer medicine shortages for children around the world ( Dr Carlos Rodriguez-Galindo - St. Jude Children’s Research Hospital, Memphis, USA )
17 Dec 2021

INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma

Prof Meral Beksac and Prof Roman Hájek
INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma ( Prof Meral Beksac and Prof Roman Hájek )
15 Dec 2021

Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL

Dr Michael Bishop - University of Chicago, Chicago, USA
Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL ( Dr Michael Bishop - University of Chicago, Chicago, USA )
14 Dec 2021

Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase

Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA
Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase ( Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA )
14 Dec 2021

Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA
Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2021

Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups

Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston, USA
Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups ( Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2021

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM

Dr Martin Kaiser - The Institute of Cancer Research, London UK
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM ( Dr Martin Kaiser - The Institute of Cancer Research, London  UK )
12 Dec 2021

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM

Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )
12 Dec 2021

Latest in combination therapy for NDMM patients

Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA
Latest in combination therapy for NDMM patients ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )
12 Dec 2021

Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
11 Dec 2021